HC Wainwright & Co. Reiterates Buy on Revance Therapeutics, Maintains $41 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Revance Therapeutics (NASDAQ:RVNC) and maintained a price target of $41.
August 15, 2023 | 10:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Revance Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $41.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Revance Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100